References
- Boolaky SH, Nuckchady DC. Risk factors for acquiring multi-drug resistant organisms in the intensive care unit: a single-centre study in Mauritius. Infect Dis (Lond). 2020;52(1):61–64.
- Kalanuria A, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18(2):208.
- Timsit J-F, Soubirou J-F, Voiriot G, et al. Treatment of bloodstream infections in ICUs. BMC Infect Dis. 2014;14(1):489.
- Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138.
- Higgins PG, Wisplinghoff H, Krut O, et al. A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect. 2007;13(12):1199–1201.
- Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
- Strateva T, Markova B, Marteva-Proevska Y, et al. Widespread dissemination of multidrug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase and ArmA 16S ribosomal RNA methylase in a Bulgarian university hospital. Braz J Infect Dis. 2012;16(3):307–310.
- Piperaki ET, Tzouvelekis LS, Miriagou V, et al. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–957.
- Strateva T, Sirakov I, Stoeva T, et al. Carbapenem-resistant Acinetobacter baumannii: current status of the problem in four Bulgarian university hospitals (2014–2016). J Glob Antimicrob Res. 2019;16:266–273.
- Grundmann HJ, Towner KJ, Dijkshoorn L, et al. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of Acinetobacter spp. J Clin Microbiol. 1997;35(12):3071–3077.